Literature DB >> 7218056

Cost of hypertension control at the workplace.

H S Ruchlin, M H Alderman.   

Abstract

A cost analysis of hypertension treatment at the workplace indicates that average patient cost in 1978 was $194.77. The distribution of cost is: clinical personnel, 26.7%; administrative personnel, 26.7%; drugs, 23.9%; laboratory, 3.4%; clinical supplies, 1.1%; general supplies and other operating expenses, 8.7%; equipment use, 1.0%; and rent, 2.6%. This aggregate cost is well below that reported for care provided in private practice and hospital outpatient department settings. The study further indicates that the constant dollar cost of care declines over the first three of four years and begins to stabilize at the fourth year. During the initial three-year period drug costs rise, but fewer revisits are required to attain and maintain blood pressure control. Drug utilization and the number of revisits per year stabilize at the fourth year.

Entities:  

Mesh:

Year:  1980        PMID: 7218056     DOI: 10.1097/00043764-198012000-00013

Source DB:  PubMed          Journal:  J Occup Med        ISSN: 0096-1736


  4 in total

1.  Community control of hypertension at work-site: epidemiological data of the Agusta project.

Authors:  R Fogari; G Marasi; A Zoppi; G D Malamani; A Vanasia; G Villa
Journal:  Eur J Epidemiol       Date:  1995-10       Impact factor: 8.082

2.  Job absenteeism and arterial hypertension: results of a hypertension control program.

Authors:  S Ruiz de la Fuente Tirado; P Cortina Greus; J L Alfonso Sanchez; C Saiz Sanchez; A Sabater Pons; J I Gonzalez Arraez; C Cortes Vizcaino
Journal:  Eur J Epidemiol       Date:  1992-09       Impact factor: 8.082

3.  Community control of hypertension at the worksite in a metallurgical factory: results of 1-year follow-up.

Authors:  R Fogari; L Poletti; F Tettamanti; M Daglio; A L Zoppi
Journal:  Eur J Epidemiol       Date:  1989-06       Impact factor: 8.082

4.  Prospective surveillance of hypertension in firefighters.

Authors:  Elpidoforos S Soteriades; Stefanos N Kales; Dimitrios Liarokapis; David C Christiani
Journal:  J Clin Hypertens (Greenwich)       Date:  2003 Sep-Oct       Impact factor: 3.738

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.